Q BioMed Inc. (QBIO)
OTCMKTS
· Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Jun 5, 2025, 8:00 PM EDT
Q BioMed Revenue
Q BioMed had revenue of $209.29K in the twelve months ending February 28, 2023, down -22.67% year-over-year. In the fiscal year ending November 30, 2022, Q BioMed had annual revenue of $284.35K with 45.38% growth.
Revenue (ttm)
209.29K
Revenue Growth
-22.67%
P/S Ratio
0.07
Revenue / Employee
n/a
Employees
n/a
Market Cap
14.51K
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.73B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 215.62M |
| Northwest Biotherapeutics | 1.47M |
| American Oncology Network | 1.76B |
| Silence Therapeutics | 27.70M |
Q BioMed News
- 2 years ago - Q BioMed Inc. Provides Update to Shareholders - PRNewsWire
- 2 years ago - Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Patent from United States Patent Office and Notice of Allowance for Europe - PRNewsWire
- 2 years ago - Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent from United States Patent Office - PRNewsWire
- 2 years ago - Q BIOMED ANNOUNCES ADDITION OF MULTI-MILLION DOLLAR ASSET VALUE WITH EQUITY STAKE IN MANIIN RESEARCH INC. - PRNewsWire
- 2 years ago - Q BIOMED PROVIDES SHAREHOLDER UPDATE - PRNewsWire
- 2 years ago - Q BIOMED ANNOUNCES ISSUANCE OF PATENT FOR GROUNDBREAKING GDF15 BIOMARKER - PRNewsWire
- 3 years ago - Traders News Source Senior Editor Mark Roberts Interviews Denis D Corin, CEO and Chairman Q BioMed Inc. - Accesswire
- 3 years ago - Q BioMed Outlines Strategy and Value Proposition in Multi-Billion Dollar Markets - PRNewsWire